Get Started

Home Domains Pharmaceutical Research

Pharmaceutical Research

Pharmaceutical research explained: drug discovery stages, target validation, lead optimisation, ADMET screening, preclinical methods and how to read the evidence.

Target → CandidateDomain guideFree to readUpdated 2026-10-13

This guide is educational. It is not medical advice, prescribing guidance or a statement about the safety, efficacy or regulatory status of any medicine. For personal medical questions, consult a qualified healthcare professional.

Pharmaceutical research is a field defined by probability and attrition. Thousands of molecules are considered, a handful are tested in people, and a very small number reach patients. Understanding why — and where the bottlenecks sit — is more useful than memorising a list of drug classes.

This guide follows the order a real programme follows: the target, the molecules, the properties that decide usability, the preclinical evidence, and finally the clinical and regulatory record. Computational methods appear where they are actually used, as filters and hypotheses, not as replacements for experiments.

Read the notice at the top of this page before using anything here: this is education about how the field works, not guidance about anyone’s treatment.

How a medicine comes to exist

A medicine is the survivor of a long elimination process. Understanding the shape of that process — discovery, preclinical work, three phases of clinical testing, then regulatory review — explains why the timeline is measured in years and why most candidates do not make it.

  • Discovery: find a biological target, find molecules that act on it, and improve them until they are worth testing.
  • Preclinical: safety, dosing and manufacturing questions answered in cells and animal models before any human exposure.
  • Clinical phases: I asks about safety in a small group, II about signal of effect, III about benefit against a comparator at scale.
  • Regulatory review decides whether the evidence supports approval, and post-market monitoring continues afterwards.
  • Most candidates that enter clinical testing do not reach approval — attrition is the defining feature of the field, not an exception.

Targets: identification and validation

A target is a molecule in the body whose modulation should change the course of a disease. Choosing the wrong one wastes years, so validation is about evidence that changing the target actually changes the biology.

  • Evidence from human genetics carries more weight than an association found in cells alone.
  • Tools that modulate the target — chemical probes, antibodies, genetic perturbation — are how causality gets tested.
  • Check that the target is present where it matters: right tissue, right cell type, right time.
  • Consider safety early: a target expressed widely in essential tissues is a risk, not a detail for later.
  • Distinguish a validated target from a popular one; the literature contains both.

Hits, leads and optimisation

Once a target is credible, the search for molecules begins. Hits come from screening, fragment work or structure-based design; lead optimisation turns a hit into something with the right potency, selectivity and behaviour in the body.

  • Structure-activity relationships: change one part of the molecule, measure the effect, and build a model of what matters.
  • Potency is necessary and insufficient — selectivity against related targets is what prevents side effects.
  • Optimisation is a multi-objective problem: potency, selectivity, solubility, stability, permeability and safety all trade against each other.
  • Formulation and route of administration are design decisions, not afterthoughts.

ADMET and computational screening

Absorption, distribution, metabolism, excretion and toxicity decide whether a potent molecule is also a usable one. Computational models filter candidate lists before expensive experiments, and their uncertainty is part of the result.

  • Absorption and permeability: can the molecule reach the target tissue in a useful concentration?
  • Metabolism: how quickly is it broken down, and into what — some metabolites are the problem, not the parent drug.
  • Toxicity prediction: models flag risk; they cannot clear a compound.
  • Simple property filters (molecular weight, lipophilicity, hydrogen bonding) remain useful as sanity checks, not as verdicts.
  • Every in-silico prediction is a hypothesis about an experiment you have not run yet.

Preclinical methods and their limits

Cell models, animal models, biomarkers and pharmacokinetic measurement are the evidence base before human testing. Each has a domain of validity, and knowing where a model stops predicting human biology is a core research skill.

  • Cell-based assays are fast and mechanistic; they cannot reproduce whole-body pharmacology.
  • Animal models capture systems biology but differ from humans in metabolism, immune response and physiology.
  • Pharmacokinetics — how concentration changes over time — often explains failures attributed to efficacy.
  • Biomarkers must be validated as measures of the thing they claim to measure.
  • Ethical and regulatory oversight of animal research exists for good reasons; study design must justify the use.

Reading the evidence like a researcher

Pharmaceutical claims arrive through papers, trial registries and regulator documents. Reading them at source — and knowing what a study cannot show — is the difference between understanding a field and repeating its marketing.

  • Primary literature in PubMed, and preprints clearly labelled as not yet peer reviewed.
  • Trial registries for design, endpoints and results, including trials that were never published.
  • Regulator documents and product labels for approved indications, warnings and dosing — the closest thing to an authoritative summary.
  • Watch for surrogate endpoints: a marker moving is not automatically a patient benefit.
  • Distinguish statistical significance from clinical relevance, and relative risk from absolute risk.

Learning path

Four stages, each ending in something you can show — a prepared file, a figure, a reproducible run. The order matters more than the speed.

Start

Biology and pharmacology foundations

Cell biology, receptors and enzymes, and how a molecule interacts with a target — enough to follow the rest of the field without hand-waving.

Follow the pipeline

Target to candidate

Trace one real programme from target identification to a candidate, reading the assays and decision points at each stage.

Add computation

Screening and prediction

Use ADMET properties and docking as filters, and state precisely what each prediction can and cannot support.

Read critically

Evidence at source

Work through a trial report and a regulator label for a medicine you know, and separate what was measured from what was concluded.

Tools this domain uses

Open-source and freely available — that is what we teach. Commercial platforms exist, but none of them are required to learn the work.

  • PubChemCompound records, bioactivity and property data — the fastest way to ground a molecule in measured facts.
  • ChEMBLCurated bioactivity data across targets, with the assay context that makes the numbers usable.
  • RCSB PDBExperimental structures of targets and target–ligand complexes.
  • PubMedPrimary literature search, including the methods sections where the real constraints are described.
  • ClinicalTrials.govTrial registries for design, endpoints and results — including studies whose results are inconvenient.
  • Guide to PharmacologyCurated target and ligand information maintained by the British Pharmacological Society and IUPHAR.

Still being built

Listed openly so nothing here is mistaken for something you can use today. None of these are published yet.

  • Annotated walkthrough of one approved medicine’s development history — In development — not published yet
  • ADMET property checklist with public dataset references — In development — not published yet

Questions learners ask

How long does it take to develop a new medicine?

Typically a decade or more from discovery to approval, with the clinical phases alone running for several years. Timelines vary widely by therapeutic area and are frequently revised.

What are the phases of a clinical trial?

Phase I tests safety and dosing in a small number of participants. Phase II looks for evidence of effect and refines dosing. Phase III compares the treatment against a control in a larger population to establish benefit and risk. Some programmes also run a Phase IV after approval to monitor real-world use.

Why do so many drug candidates fail?

Commonly because of unacceptable toxicity, poor pharmacokinetics, or a lack of real clinical benefit even when the target was engaged. Failure at a late stage is the field’s central economic problem.

Can computational methods replace laboratory testing?

No. Docking, ADMET models and machine learning prioritise which experiments to run. They do not establish safety, efficacy or regulatory acceptability.

Do I need a pharmacy or medical degree to work in this area?

No. Pharmaceutical research employs biologists, chemists, engineers, data scientists and clinicians. The shared requirement is understanding the evidence standards of the field.

01/Related domains